Rayzebio Inc 's ROA from the third quarter of 2023 to the third quarter of and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Rayzebio Inc 's ROA in the third quarter of 2023?
Rayzebio Inc achieved a return on average assets (ROA) of 164.76 % in its third quarter of 2023, this is above RYZB's average return on assets of 0%.
Rayzebio Inc assets over the 12 months ending in its third quarter of 2023 are valued at $229 million

ROA decreased relative to the period ending Sep 30 2022, due to the decline in net income.

However, within the Healthcare sector Rayzebio Inc achieved the highest return on assets. While the total ranking for ROA unchanged, relative to the third quarter of 2022 at no. .

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2023) III. Quarter	(Sep 30 2022) III. Quarter
Y / Y Total Assets Change	-	-	-	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	377	395	0	0	0
Return On Assets (TTM)	164.76 %	497.1 %	-	-	-
RYZB's Total Ranking	#	#	#	#	#
Total Assets (TTM) in million	597	318	0	0	0
Seq. Total Assets Change	87.82 %	-	-	-	-
Seq. Net Income Change	-	-	-	-	-

RYZB's 5 Years Annual ROA >> Back to RYZB Management Effectiveness >> Compare RYZB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Assets Statistics
High	Average	Low
0 %	0 %	0 %

Financial Statements
Rayzebio Inc 's Assets	$ 597 million	RYZB's Balance sheet
Rayzebio Inc 's Income	$ -18 million	Quarterly RYZB's Income Statement
RYZB's Income by Division		See RYZB's Income by Division

Annual Return On Assets	FY	FY	FY	FY	FY
Y / Y Total Assets Change	-	-	-	-	-
Total Assets in million	0	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	0	0	0	0	0
Annual Return On Assets	-	-	-	-	-

RYZB's 5 Years Annual ROA >> Back to RYZB Management Effectiveness >> Compare RYZB ROA to its Competitors

More Return On Assets Ratios
RYZB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RYZB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RYZB's Competitors
Subscribers only: Roa for Rayzebio Inc 's Suppliers
Subscribers only: Return On Assets for RYZB's Customers

You may also want to know
RYZB's Roi	RYZB's Inventory Turnover Ratio	RYZB's Growth Rates	RYZB's Dividend Comparisons
	RYZB's Profitability Ratios	RYZB's Asset Turnover Ratio	RYZB's Dividend Growth
RYZB's Roe	RYZB's Valuation Ratios	RYZB's Financial Strength Ratios	RYZB's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector	ROA
Regen Biopharma Inc	241.63 %
Ir med Inc	227.71 %
Tff Pharmaceuticals Inc	224.43 %
Evofem Biosciences Inc	221.97 %
Gyre Therapeutics Inc	153.95 %
Biocorrx Inc	135.62 %
Therapeuticsmd Inc	107.47 %
Inhibitor Therapeutics Inc	98.66 %
Glucotrack Inc	68.42 %
Biomx Inc	65.90 %
Agile Therapeutics Inc	64.16 %
Longduoduo Co Ltd	62.76 %
Scynexis Inc	62.58 %
Opus Genetics Inc	59.88 %
Dariohealth Corp	50.84 %
Molecular Templates Inc	40.96 %
Northview Acquisition Corp	37.76 %
Elite Pharmaceuticals Inc	36.88 %
Entera Bio Ltd	35.29 %
Star Equity Holdings Inc	34.97 %
Zymeworks Inc	34.09 %

Date modified: 2026-08-31T17:00:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.